201 related articles for article (PubMed ID: 38164943)
41. Comprehensive Analysis of Immune Implication and Prognostic Value of
Zeng Y; Zhang Z; Chen H; Fan J; Yuan W; Li J; Zhou S; Liu W
Front Oncol; 2021; 11():798425. PubMed ID: 35047409
[TBL] [Abstract][Full Text] [Related]
42. Comprehensive characterization of immunogenic cell death in acute myeloid leukemia revealing the association with prognosis and tumor immune microenvironment.
Chen Y; Qiu X; Liu R
BMC Med Genomics; 2024 Apr; 17(1):107. PubMed ID: 38671491
[TBL] [Abstract][Full Text] [Related]
43. A more novel and powerful prognostic gene signature of lung adenocarcinoma determined from the immune cell infiltration landscape.
Ma C; Li F; He Z; Zhao S
Front Surg; 2022; 9():1015263. PubMed ID: 36311939
[TBL] [Abstract][Full Text] [Related]
44. The prognosis, chemotherapy and immunotherapy efficacy of the SUMOylation pathway signature and the role of UBA2 in lung adenocarcinoma.
Yu L; Lin N; Ye Y; Zhuang H; Zou S; Song Y; Chen X; Wang Q
Aging (Albany NY); 2024 Feb; 16(5):4378-4395. PubMed ID: 38407971
[TBL] [Abstract][Full Text] [Related]
45. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.
Yang J; Liu K; Yang L; Ji J; Qin J; Deng H; Wang Z
Front Immunol; 2023; 14():1174762. PubMed ID: 37287976
[TBL] [Abstract][Full Text] [Related]
46. m7G-Associated subtypes, tumor microenvironment, and validation of prognostic signature in lung adenocarcinoma.
Wang G; Zhao M; Li J; Li G; Zheng F; Xu G; Hong X
Front Genet; 2022; 13():954840. PubMed ID: 36046251
[No Abstract] [Full Text] [Related]
47. Construction of shared gene signature between rheumatoid arthritis and lung adenocarcinoma helps to predict the prognosis and tumor microenvironment of the LUAD patients.
Shi L; Zou H; Yi J
Front Mol Biosci; 2023; 10():1314753. PubMed ID: 38268722
[No Abstract] [Full Text] [Related]
48. Six CT83-related Genes-based Prognostic Signature for Lung Adenocarcinoma.
Wang Y; Zhang G; Wang R
Comb Chem High Throughput Screen; 2022; 25(9):1565-1575. PubMed ID: 34259140
[TBL] [Abstract][Full Text] [Related]
49. Comprehensive analysis identifies DNA damage repair-related gene HCLS1 associated with good prognosis in lung adenocarcinoma.
Liu T; Hu A; Chen H; Li Y; Wang Y; Guo Y; Liu T; Zhou J; Li D; Chen Q
Transl Cancer Res; 2023 Oct; 12(10):2613-2628. PubMed ID: 37969376
[TBL] [Abstract][Full Text] [Related]
50. A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.
Wang X; Zhao C; Huang D; Liu Z; Liu M; Lin F; Lu Y; Jia J; Lin L; Lin X; Li H; Chen Z
Front Immunol; 2022; 13():923533. PubMed ID: 35860262
[TBL] [Abstract][Full Text] [Related]
51. Tumor microenvironment related novel signature predict lung adenocarcinoma survival.
Chen J; Zhou R
PeerJ; 2021; 9():e10628. PubMed ID: 33520448
[TBL] [Abstract][Full Text] [Related]
52. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
53. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
Front Immunol; 2022; 13():950001. PubMed ID: 36091041
[TBL] [Abstract][Full Text] [Related]
54. Single-cell sequencing analysis and transcriptome analysis constructed the macrophage related gene-related signature in lung adenocarcinoma and verified by an independent cohort.
Li R; Tong R; Zhang Z; Deng M; Wang T; Hou G
Genomics; 2022 Nov; 114(6):110520. PubMed ID: 36372305
[TBL] [Abstract][Full Text] [Related]
55. Identification and validation of molecular subtype and prognostic signature for lung adenocarcinoma based on neutrophil extracellular traps.
Zuo Y; Leng G; Leng P
Pathol Oncol Res; 2023; 29():1610899. PubMed ID: 37143472
[No Abstract] [Full Text] [Related]
56. Prognostic significance of pyroptosis-related factors in lung adenocarcinoma.
Lin X; Zhou T; Hu S; Yang L; Yang Z; Pang H; Zhou X; Zhong R; Fang X; Yu Z; Hu K
J Thorac Dis; 2022 Mar; 14(3):654-667. PubMed ID: 35399245
[TBL] [Abstract][Full Text] [Related]
57. Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma.
Zhou X; Xu R; Lu T; Wang C; Chang X; Peng B; Shen Z; Yao L; Wang K; Xu C; Shi J; Zhang R; Zhao J; Zhang L
Sci Rep; 2023 Aug; 13(1):13305. PubMed ID: 37587188
[TBL] [Abstract][Full Text] [Related]
58. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
Front Immunol; 2022; 13():749241. PubMed ID: 35529878
[TBL] [Abstract][Full Text] [Related]
59. Identification and validation of a hypoxia-immune signature for overall survival prediction in lung adenocarcinoma.
Li Y; Huang H; Jiang M; Yu N; Ye X; Huang Z; Chen L
Front Genet; 2022; 13():975279. PubMed ID: 36263421
[No Abstract] [Full Text] [Related]
60. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Wang J; Zhan X
Front Immunol; 2021; 12():752643. PubMed ID: 34887858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]